Previously, we found that some Rac1-driven BRAFi-resistant melanoma cells showed a vulnerability to combination treatment with BRAFi and the selective Src kinase family inhibitor, saracatinib (ref. [14] and Supplementary Fig. S5D). This evidence concerns the gene RAC1 and melanoma.